Ascent Industries Co. · NASDAQ:ACNT
Ascent Industries — iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025
19 slides from Ascent Industries's conference presentation, Dec 9, 2025
Slide 1: iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025
iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 Ascent I ndustries Co. | Nasdaq: ACNT
Slide 2: Forward Looking Statement Safe Harbor and Non-GAAP Information
Forward Looking Statement Safe Harbor and Non-GAAP Information Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not histo
Slide 3: CEO & CFO Have a Proven Track Record of Making Good Specialty Chemical Companies Great
CEO & CFO Have a Proven Track Record of Making Good Specialty Chemical Companies Great Kitchen, Kavalauskas, and many of their management team counterparts have previously worked together, a synergy that has had an undeniable impact on Ascent's operational and financial performance since assuming th
Slide 4: After 75 years, we are going back to our roots as a Specialty Chemical Company
After 75 years, we are going back to our roots as a Specialty Chemical Company Company Founded Synalloy Manufacturers Palmer of Specialty Pipe Marcegaglia USA Divestiture of Blackman Uhler Corporation Chemicals Texas Tanks & Tube Synalloy Corporation DanChem Specialty Pipe Portfolio Technologies Ind
Slide 5: Highlights Since Management Team Installed
Increase in TTM Adj.Profit EBITDA 100.2% 171.6% Increase in TTM Gross TTM Increase / $8.2M TTM Increase / $10.9M; Gross Margin from 7% to 23% Continuing Operations Performance Through Q32025 Continuing Operations Performance Through Q32025 Highlights Since 100.2% Increase in TTM Adj. EBITDA TTM Incr
Slide 6: Who We Are, What We Do & How We Operate
Pure-Play Who We Are, What We Do & Specialty Chemicals Company How We Operate
Slide 7: Our Strategy & Operating Model
Our Strategy & Operating Model Outcomes over everything. We’re building a platform that solves real problems across the value chain, not just by providing products or capacity, but by offering a full suite of services: formulation development, reaction capabilities, blending, packaging, logistics, r
Slide 8: Integrated Capabilities and Agile Business Models for Superior Customer Outcomes
Integrated Capabilities and Agile Business Models for Superior Customer Outcomes SOLUTIONS BUSINESS MODEL Primary Formulation Toll Custom Buy, Build & Development Scale-Up Reaction Blending Warehousing Logistics Regulatory Customization Products Manufacturing Manufacturing Operate Ascent (CaaS Model
Slide 9: We deliver tailored specialty-chemistry solutions at scale across high-value segments
We deliver tailored specialty-chemistry solutions at scale across an array of high-value segments Life Sciences Performance Materials HI&I Personal Care Oil & Gas Water Treatment CASE $15 BN TAM | 5-6% CAGR $15 BN TAM | 4-5% CAGR $20 BN TAM | 4.5-5.5% CAGR $40 BN TAM | 6-8.5-6% CAGR Agriculture Pulp
Slide 10: Within an asset base capable of supporting significant growth with minimal capital reinvestment
Within an asset base capable of supporting significant growth with minimal capital reinvestment Ample, underutilized capacity Requiring minimal capital reinvestment to support growth (M USD) provides a capital-light, low-risk foundation for outsized growth $1.6 $1.6 $1.4 $1.3 Danville, VA Fountain I
Slide 11: While filling the plants with higher margin business that is more predictable and reliable
While filling the plants with higher margin business that is more predictable and reliable Portfolio Defined, Refined & Rebranded Business Model (% of Revenue) Gross Margin from Continuing Operations 28.1% 26.1% YTD2025 28% 72% 17.2% 2024 27% 73% 13.2% 5.0% 2023 10% 90% Product Sale Custom Mfg. 2023
Slide 12: Driven by a Strong & Growing Selling Pipeline
YTD (Q1-Q3) Pipeline Conversion By Business Model Driven by a Strong & 73 3.01 16.4% 35% Custom M f g. 65% P RO J E C T SALES CONVERSION Product Growing Selling COUNT C YC L E ( M O N T H S ) * R AT E * * Sales *Calculated from initial **Calculated as wins divided customer engagement to by all close
Slide 13: 2026-2030 The Path Forward
2026-2030 The Path Forward Durable Earnings-Growth
Slide 14: Simple and Clear EBITDA Drivers
Simple and Clear EBITDA Drivers Management Turnaround Organic Growth / Operating Leverage Inorganic Growth Structural cost savings with emphasis on strategic sourcing Enhanced commercial strategy to grow share of higher- Searching for good businesses to make great Aggressive management of co
Slide 15: And strong liquidity to support investor-friendly capital allocation priorities
And strong liquidity to support investor- friendly capital allocation priorities Every internal investment and acquisition is about accelerating progress, creating synergies that make sense, and delivering real, sustainable value. It's not only about size, it's about outcomes that matter, both strat
Slide 16: Why invest in Ascent?
Why invest in ? Portfolio Optimized Strategic clarity. Focus. Efficiency. Stabilized and Growth Ready Predictability. Confidence. Credibility. Reduced risk. Growth Capacity In-Place Optionality. Scale. Margin. Growth. Resilience. Near-Term Upside Undervalued, leverage multiple upside. Strong Balance
Slide 17: Ryan Kavalauskas, Chief Financial Officer
Ryan Kavalauskas Chief Financial Officer rkavalauskas@ascentco.com 17
Slide 18: Appendix
Appendix 18
Slide 19: Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA
Consolidated EBITDA and Adjusted EBITDA from Continuing Operations: FINANCIALS Three Months Ended Nine Months Ended September 30, September 30, ($ in thousands) 2025 2024 2025 2024 Consolidated Net loss from continuing operations $ (125) $ (7,801) $ (4,577) $ (12,731) Adjustments: Interest expense (
Ascent Industries — iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on 6ix